ZS Pharma Announces Positive Interim Results From a Long-Term Safety Study of ZS-9
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
ZS Pharma (ZSPH) Reports Interim Results From Long-Term Safety Study of ZS-9
November 9, 2015 7:14 AM ESTZS Pharma, Inc. (Nasdaq: ZSPH) presented interim results from ZS005, a long-term safety and efficacy study of ZS-9 (sodium zirconium cyclosilicate), an investigational treatment for hyperkalemia, at a late-breaking poster presentation during the American Society of Nephrology's (ASN) Kidney Week 2015.
... More